tiprankstipranks
PainReform says IVR rates of PRF-110 superior for post-surgical pain products
PremiumThe FlyPainReform says IVR rates of PRF-110 superior for post-surgical pain products
15d ago
PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
PremiumPress Releases
PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
15d ago
PainReform Shareholders Approve Key Proposals
PremiumCompany Announcements
PainReform Shareholders Approve Key Proposals
16d ago
PainReform reports 2023 EPS ($7.14) vs. ($8.13) last year
PremiumThe FlyPainReform reports 2023 EPS ($7.14) vs. ($8.13) last year
2M ago
PainReform Provides Year-End Business Update
PremiumPress Releases
PainReform Provides Year-End Business Update
2M ago
PainReform to Present at the Microcap Conference in Atlantic City
PremiumPress Releases
PainReform to Present at the Microcap Conference in Atlantic City
3M ago
PainReform Provides Business Update for the Third Quarter of 2023
PremiumPress ReleasesPainReform Provides Business Update for the Third Quarter of 2023
5M ago
PainReform announces plans to commence second part of Phase 3 trial of PRF-110
PremiumThe Fly
PainReform announces plans to commence second part of Phase 3 trial of PRF-110
8M ago
PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File
PremiumPress Releases
PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100